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Deep Vein Thrombosis (DVT) and the associated condition of Pulmonary Embolism (PE) are the most common cause of
unexpected death in developed nations.  DVT is an internal clot formed in one of the body's deep veins, typically in the leg. 
If a part of the clot breaks free and moves into the lung, it can lead to pulmonary embolism (PE) which is often fatal.
D-dimer is a recognised marker for the diagnosis of thrombus and is routinely used by skilled technical staff as part of an 
ELISA technique in hospital laboratories.  Current D-dimer point-of-care tests are not sufficiently quantitative to allow them 
to be used to exclude DVT/PE.   As a consequence,  clinicians  need to rely on the use of expensive Doppler ultrasound 
imaging  (DUS),  creating  additional  pressure  on national  health  services1.  The DUS examination  can take several  days, 
during which time heparin is required to be administered to the patient.  There is increasing in the development of low cost  
Lab-on-a-chip systems that will allow chemical and biological processing by non-specialist staff. A low cost, easy to use, 
portable and quantitative device for DVT/PE would be highly desirable since it would provide reliable diagnosis and aid 
faster treatment and recovery as well as lower healthcare provider costs.
We report on the development of a portable system for the quantification of D-dimer in whole blood through the use of a 
label-free impedimetric approach for monitoring ligand-receptor (antigen-antibody) immunoassay.  The system, comprises a 
disposable  cartridge,  carrying  receptor  ontop  electrochemical  transducer  and  allowing  sample  transport,  and  a reusable 
portable  hand-held  reader.  The  electrochemical  transducers  being  developed  include  three-point  and  inter-digitated 
electrodes (IDEs). The IDEs have a higher surface interface than 3-point electrodes and consequently the higher surface 
area will result in higher measurement sensitivity. Further in the case of IDEs, simulation shows that 80% of the current is 
found to flow in a layer not higher than 2L/3 above the surface (where L = inter-electrode distance). As a consequence, all 
of the electric field will be concentrated close to surface of the electrodes where the immobilised D-dimer ligand binding 
occurs. Immobilisation of the His-tag and Avitag model antibody has been carried out by electrodeposition of polypyrrole. 
We have also demonstrated contact printing immobilization approach using amine terminated D-dimer antibody onto gold 
substrates as a precursor for printing directly onto the electrodes. A tagged D-dimer antibody immobilized to a three-point 
electrode structure for D-dimer detection  in buffer and plasma has respectively dynamic ranges of 100pg/ml – 500ng/ml 
(standard deviation with four electrodes of 9.3%)  and  100pg/ml – 100ng/ml.  
The disposable cartridge system is developed as two separate pieces for subsequent joining. The bottom piece comprises the 
electrochemical transducer structure, with the bioreceptor as well as electrical connectivity test electrodes and temperature 
sensors.  The  cartridge  lid  carries  the  necessary  elements  to  transport  blood  over  the  electrochemical  transducer.  The 
cartridge system is being prototyped using hot embossing and micro-injection moulding but will allow roll-to-roll mass 
manufacturing technologies to reduce costs.
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